Detail akcie Mode online

Business Summary: Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Sygnis SA revenues decreased 47% to PLN3.8M. Net loss decreased 42% to PLN2.9M. Revenues reflect Sales of Goods and Materials decrease of 49% to PLN2.9M, Sales of Products decrease of 36% to PLN934K. Lower net loss reflects Salaries decrease of 46% to PLN2.3M (expense), Outsoursing decrease of 45% to PLN1.2M (expense), Social Securities decrease of 66% to PLN316K (expense).